Quotient Sciences Header

Quotient Sciences Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"reMYND","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ReMynd Commences First-in-Human Trial of ReS19-T Alzheimer\u2019s Program","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"BELGIUM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"reMYND"},{"company":"reMYND","sponsor":"Korys Investments","pharmaFlowCategory":"D","amount":"$29.0 million","upfrontCash":"Undisclosed","newsHeadline":"reMYND extends Series B funding to EUR 24 million","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"BELGIUM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"reMYND"},{"company":"reMYND","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"reMYND\u2019s ReS19-T Program, Managing Calcium Homeostasis for Alzheimer\u2019s, Has Moved to MAD phase After Demonstrating Strong Safety In SAD Phase","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"BELGIUM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"reMYND"},{"company":"Novadip Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novadip Biosciences Reports Positive Data From phase I Study of NVD-001 For Spinal Fusion","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"BELGIUM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Novadip Biosciences"},{"company":"Syndesi Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$1,000.0 million","upfrontCash":"$130.0 million","newsHeadline":"AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Portfolio","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"BELGIUM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Syndesi Therapeutics"},{"company":"Confo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Confo Therapeutics Doses First Subjects in Phase 1 Clinical Trial of CFTX-1554 for the Treatment of Neuropathic Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"BELGIUM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Confo Therapeutics"},{"company":"Confo Therapeutics","sponsor":"Flanders Innovation & Entrepreneurship","pharmaFlowCategory":"D","amount":"$1.8 million","upfrontCash":"Undisclosed","newsHeadline":"Confo Therapeutics Awarded EUR 1.7M VLAIO Grant to Expand Application of ConfoBody\u00ae Drug Discovery and Development Technology in Rare Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"BELGIUM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Confo Therapeutics"}]

Confo Therapeutics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Confo Therapeutics Awarded EUR 1.7M VLAIO Grant to Expand Application of ConfoBody® Drug Discovery and Development Technology in Rare Diseases

Details:

The grant will enable to further extend its current universal ConfoBody®, Cb35, toward other G proteins. The funds will also be used to identify additional universal ConfoBodies® for use in ConfoSensor® screening technology and lead neuropathic pain program, CFTX-1554.

Lead Product(s): CFTX-1554

Therapeutic Area: Neurology Product Name: CFTX-1554

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Flanders Innovation & Entrepreneurship

Deal Size: $1.8 million Upfront Cash: Undisclosed

Deal Type: Financing June 28, 2022

ASK
US

Upload
your Pipeline Activity

Confo Therapeutics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Confo Therapeutics Doses First Subjects in Phase 1 Clinical Trial of CFTX-1554 for the Treatment of Neuropathic Pain

Details:

CFTX-1554, a novel inhibitor of the angiotensin II type 2 receptor (AT2R), is being developed as a non-opioid approach to the treatment of neuropathic pain, while avoiding centrally mediated side effects, such as addiction and sedation.

Lead Product(s): CFTX-1554

Therapeutic Area: Neurology Product Name: CFTX-1554

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 10, 2022

ASK
US

Upload
your Pipeline Activity

Syndesi Therapeutics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Portfolio

Details:

Acquisition will advance the research of novel, for the treatment of cognitive impairment associated with neuropsychiatric and neurodegenerative disorders including its lead molecule, SDI-118, small molecule currently in Phase 1b, which is evaluated to target nerve terminals.

Lead Product(s): SDI-118

Therapeutic Area: Neurology Product Name: SDI-118

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: AbbVie Inc

Deal Size: $1,000.0 million Upfront Cash: $130.0 million

Deal Type: Acquisition March 01, 2022

ASK
US

Upload
your Pipeline Activity

reMYND

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

reMYND’s ReS19-T Program, Managing Calcium Homeostasis for Alzheimer’s, Has Moved to MAD phase After Demonstrating Strong Safety In SAD Phase

Details:

RES19-T has shown to produce an acute response, restoring calcium homeostasis and synaptic plasticity, aim to address the disease at its root and restore cognition in patients by reducing the cellular damage associated with memory loss.

Lead Product(s): RES19-T

Therapeutic Area: Neurology Product Name: RES19-T

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 21, 2021

ASK
US

Upload
your Pipeline Activity

Novadip Biosciences

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Novadip Biosciences Reports Positive Data From phase I Study of NVD-001 For Spinal Fusion

Details:

NVD-001 is Novadip’s first generation autologous cell-based osteogenic (bone healing) product derived from the Company’s proprietary tissue regeneration platform. Study met its primary endpoint. NVD-001 showed a favorable safety profile over a two-year observation period.

Lead Product(s): NVD-001

Therapeutic Area: Neurology Product Name: NVD-001

Highest Development Status: Phase I Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 15, 2021

ASK
US

Upload
your Pipeline Activity

reMYND

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

reMYND extends Series B funding to EUR 24 million

Details:

Proceeds from the fundraise will allow completion of proof-of-concept clinical trials for both the Alzheimer’s and the diabetes programs. A first-in-human trial of RES19-T for Alzheimer’s was initiated in 2020.

Lead Product(s): RES19-T

Therapeutic Area: Neurology Product Name: RES19-T

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Korys Investments

Deal Size: $29.0 million Upfront Cash: Undisclosed

Deal Type: Series B Financing January 21, 2021

ASK
US

Upload
your Pipeline Activity

reMYND

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

ReMynd Commences First-in-Human Trial of ReS19-T Alzheimer’s Program

Details:

RES19-T, a first-in-class small molecule, represents a novel approach to treat Alzheimer’s Disease (AD), aiming to address the disease at its root and restore cognition in patients by reducing the cellular damage associated with memory loss.

Lead Product(s): RES19-T

Therapeutic Area: Neurology Product Name: RES19-T

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 03, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY